Nureca Limited has informed the Exchange regarding Appointment of Mr.Chander Kant as Chief Financial Officer of the company w.e.f. Jun 27, 2026.
NURECA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Nureca's Board meeting on May 29, 2026 approved multiple items. CFO Mr. Naresh Gupta resigned effective June 26, 2026 citing better career opportunities, and Mr. Chander Kant (Manager Finance) was promoted to CFO from June 27, 2026. FY26 standalone revenue was Rs 1,472.10 million, up 28% from Rs 1,146.40 million in FY25. Net profit after tax was Rs 2.97 million vs loss of Rs 6.68 million in FY25. However, Q4 FY26 showed a loss of Rs 66.25 million due to Rs 83.37 million fair value loss on investments. The Board also reappointed Mr. Aryan Goyal (CEO) and Mr. Saurabh Goyal (MD), and appointed Ms. Smita Goyal as Additional Whole-Time Director—all family members. Additionally, the Board approved Rs 100 crore capex for manufacturing medical devices and healthcare products at Derabassi, Punjab, plus land purchase for future expansion. The 10th AGM is scheduled for July 28, 2026.
The CFO resignation and immediate internal replacement is neutral—internal promotion minimizes disruption. Family concentration on board is a governance concern for some investors. Strong revenue growth but Q4 loss and Rs 100 crore capex commitment are material for cash flow and future earnings visibility.